Many multiple myelomas: making more of the molecular mayhem.
Many multiple myelomas: making more of the molecular mayhem.
复制标题
DOI：
10.1182/asheducation-2011.1.344
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
Bergsagel PL
中科院分区：
文献类型：
--
作者：
Chesi M;Bergsagel PL
多发性骨髓瘤（MM）是一种恶性肿瘤，其同型转换，BM定位浆细胞，经常导致骨破坏，BM衰竭和死亡。重要的分子亚群由三种类型的复发性免疫球蛋白基因易位和高二倍体确定，两者都影响疾病病程。从临床角度来看，识别携带t（4;14）易位的MM患者至关重要，这种易位存在于15%的骨髓瘤中，并与WHSC1/MMSET和FGFR3的失调有关。这些患者都应该接受硼替佐米作为初始诱导治疗的一部分，因为这已被证明可以显着延长生存期。相反，易位影响转录因子MAF家族、del17p或基因表达谱（GEP）定义的高危疾病的患者预后较差，任何干预措施都无法显著改善。这些患者应该参加创新的临床试验。其余的细胞周期蛋白D易位或高二倍体患者在大多数治疗中表现良好，目标应该是在控制疾病的同时尽量减少毒性。
Multiple myeloma (MM) is malignancy of isotype-switched, BM-localized plasma cells that frequently results in bone destruction, BM failure, and death. Important molecular subgroups are identified by three classes of recurrent immunoglobulin gene translocations and hyperdiploidy, both of which affect disease course. From a clinical standpoint, it is critical to identify MM patients carrying the t(4;14) translocation, which is present in 15% of myelomas and is associated with dysregulation of WHSC1/MMSET and often FGFR3. These patients should all receive bortezomib as part of their initial induction treatment because this has been shown to significantly prolong survival. In contrast, patients with translocations affecting the MAF family of transcription factors, del17p, or gene-expression profiling (GEP)–defined high-risk disease appear to have a worse prognosis that is not dramatically improved by any intervention. These patients should be enrolled in innovative clinical trials. The remaining patients with cyclin D translocations or hyperdiploidy do well with most therapies, and the goal should be to control disease while minimizing toxicity.
登录
查看更多内容
影响因子：
168.9
作者：
Dispenzieri, Angela;Katzmann, Jerry A.;Kyle, Robert A.;Larson, Dirk R.;Melton, L. Joseph, III;Colby, Colin L.;Therneau, Terry M.;Clark, Raynell;Kumar, Shaji K.;Bradwell, Arthur;Fonseca, Rafael;Jelinek, D. F.;Rajkumar, S. Vincent
通讯作者：
Rajkumar, S. Vincent
影响因子：
11.4
作者：
Chng, W-J;Huang, G. F.;Chung, T. H.;Ng, S. B.;Gonzalez-Paz, N.;Troska-Price, T.;Mulligan, G.;Chesi, M.;Bergsagel, P. L.;Fonseca, R.
通讯作者：
Fonseca, R.
影响因子：
45.3
作者：
Decaux, Olivier;Lode, Laurence;Minvielle, Stephane
通讯作者：
Minvielle, Stephane
DOI：
10.3324/haematol.2010.023697
发表时间：
2010-11-01
期刊：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
影响因子：
--
作者：
Lode, Laurence;Eveillard, Marion;Avet-Loiseau, Herve
通讯作者：
Avet-Loiseau, Herve
影响因子：
20.3
作者：
Bergsagel, PL;Kuehl, WM;Shaughnessy, J
通讯作者：
Shaughnessy, J